Off Patent
February 2026

Briviact

brivaracetam

UCB Inc

Solution (intravenous) · NDA 205837

Last listed protection ended
February 21, 2026

The FDA listed 1 patent for Briviact, and this is the day the last one ended. It is not the date a generic goes on sale.

Patents and exclusivities

  1. Ended
    Patent 6,911,461
    Claims the drug substance, the drug product and a use (U-1815, U-2130)